Biocon arm, CHAI in pact on affordable cancer therapies

Published - February 04, 2021 11:06 pm IST - Bengaluru

Biocon Biologics, a pure-play biosimilars firm and subsidiary of Biocon Ltd., has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to life-saving cancer biosimilars in more than 30 countries in Africa and Asia, as part of the Cancer Access Partnership (CAP).

As per the agreement, Biocon Biologics would aim to deliver affordable biosimilar cancer therapies in 25 countries in Africa and five countries in Asia, currently covered under CAP, led by the CHAI.

The company would initially supply bTrastuzumab and bPegfilgrastim and expand the arrangement to include other biosimilars.

The partnership was a significant step in delivering advanced cancer therapies to patients who needed them the most and ensuring equitable access to high-quality biosimilars in low- and middle-income countries, said the company.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.